nei THIS MONTH IN
PSYCHOPHARMACOLOGY
Browsing articles in "Bipolar Disorders"

 

Aripiprazole Maintena Approved for Bipolar Maintenance Treatment
August 1, 2017   

On July 28, 2017, the U.S. Food and Drug Administration approved the atypical antipsychotic Abilify Maintena (aripiprazole) as a maintenance monotherapy treatment for patients with Bipolar I disorder...
 Continue reading (Members only)
FDA Update: New Warning Added to Antipsychotic Labels
April 6, 2017   

The U.S. Food and Drug Administration (FDA) has approved a labeling update for all antipsychotic medications adding a new warning to the prescribing information....
 Continue reading (Members only)
Guidelines for the Recognition and Treatment of Depression with Mixed Features
March 10, 2017   

The Diagnostic and Statistical Manual of Mental Disorders 5th Edition (DSM-5) incorporated a "mixed features" specifier that recognizes the idea of mood disorders as lying on a spectrum and acknowledges the coexistence of subthreshold symptoms of (hypo)mania during a major depressive episode (or of subthreshold symptoms of depression co-occurring with a manic episode)...
 Continue reading
Consensus Statement on Use of Ketamine for Mood Disorders
March 9, 2017   

Based primarily on small-scale studies and numerous case reports, much excitement has been built around the use of ketamine in the treatment of mood disorder...
 Continue reading (Members only)
Methylene Blue May Help Bipolar Depression
November 14, 2016   

In a double-blind cross over study of patients with bipolar disorder being treated with lamotrigine, an active dose (195 mg) of methylene blue was compared to a low dose (15 mg) of methylene blue which served as a placebo...
 Continue reading (Members only)
Congenital Malformations Not Seen With Antipsychotic Use During Pregnancy
September 6, 2016   

Results from a large retrospective study found that antipsychotic use during pregnancy does not significantly increase the risk of birth defects. Krista F. Huybrechts, MS, PhD and colleagues examined the association between antipsychotic (AP) use during the first trimester and the risk of congenital malformations...
 Continue reading (Members only)
Implications of a Meta-Analysis of Antidepressants for Major Depressive Disorder in Children and Adolescents
July 12, 2016   

In this comprehensive network meta-analysis, the authors analyzed the efficacy and tolerability of antidepressants in the treatment of major depressive disorder (MDD) in children and adolescents. Cipriani and colleagues reviewed the results from 34 randomized clinical trials that collectively tested treatment with 14 different antidepressants in youth (mean age 9 to 18 years) with MDD. In the analysis, only fluoxetine was superior to placebo...
 Continue reading (Members only)
News from the 2016 American Psychiatric Association Annual Meeting
June 10, 2016   

Here are a few highlights from the poster sessions at the 166th annual American Psychiatric Association meeting.
 Continue reading (Members only)
Mixed Depression in Bipolar Disorder: Prevalence Rates and Clinical Correlates
April 22, 2016   

Researchers observed that hypomanic symptoms during visits with depression in patients with bipolar disorder were more common, particularly in women, than the DSM-5 diagnostic criteria may yield. A total of 907 adult patients with bipolar disorder were analyzed across 14,310 visits between 1995 and 2002...
 Continue reading (Members only)
March News and New Research
March 1, 2016   

New CDC Guidelines for Opioid Use, A Novel Risk Assessment Tool for Pediatric Persistent Postconcussion Symptoms, Predictors of New-Onset Bipolar Disorder in At-Risk Youths, and other news.
 Continue reading (Members only)
12
Top of Page